NASDAQ:VERU Veru Q3 2026 Earnings Report $2.37 -0.01 (-0.55%) As of 09:44 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Veru EPS ResultsActual EPSN/AConsensus EPS -$0.34Beat/MissN/AOne Year Ago EPSN/AVeru Revenue ResultsActual RevenueN/AExpected Revenue$1.70 millionBeat/MissN/AYoY Revenue GrowthN/AVeru Announcement DetailsQuarterQ3 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Veru Earnings HeadlinesCritical Comparison: Veru (NASDAQ:VERU) and QuidelOrtho (NASDAQ:QDEL)July 20 at 2:15 AM | americanbankingnews.comPalisade's Dan Veru talks his small cap trading playbookJuly 12, 2026 | cnbc.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 20 at 1:00 AM | Porter & Company (Ad)Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop DayJuly 7, 2026 | globenewswire.comVeru Establishes At-the-Market Equity Offering ProgramJuly 2, 2026 | tipranks.comVeru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill WegovyJune 5, 2026 | marketwatch.comSee More Veru Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Veru? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Veru and other key companies, straight to your email. Email Address About VeruVeru (NASDAQ:VERU) is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development. The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19. In parallel, Veru is developing toremifene, a selective estrogen receptor modulator repurposed to address chemotherapy-induced side effects and support women’s health applications. The company’s pipeline also encompasses exploratory programs aimed at targeting key drivers of cancer progression and acute inflammatory responses. Founded in 2010 (formerly operating as Veru Healthcare) by Dr. Mark A. Enyedy, who serves as President and Chief Executive Officer, Veru has conducted clinical studies across North America, Europe and Asia. The company maintains collaborations with academic institutions and contract research organizations to execute multi-center trials, and it has secured manufacturing partnerships to support planned commercial supply. Veru’s leadership team combines expertise in pharmaceutical development, regulatory affairs and oncology drug commercialization to guide late-stage program advancement.View Veru ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/13- 07/17Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to BenefitThe Market Sold Alcoa After Earnings—But It May Be Missing the Real StoryTSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthWhy Intuitive Surgical’s Strong Quarter Still Spooked InvestorsNetflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
